Alcoholic fatty liver disease: causes and treatment

Alcoholic fatty liver disease, also known as alcoholic fatty liver disease, is the accumulation of fat in liver cells due to regular or occasional excessive alcohol consumption. It is the earliest stage of alcohol-related liver disease and often goes unnoticed. [1]

The key clinical significance of this stage is that it is reversible: when alcohol consumption is stopped, the liver can return to normal, sometimes a few weeks of sobriety are sufficient, but the time frame depends on the initial condition and the duration of consumption. [2]

Alcohol-induced fatty liver disease is often perceived as a "benign finding," but it is a signal that the liver is already responding to toxic exposure. With continued use, some people develop inflammation, then fibrosis, and eventually cirrhosis and the risk of liver cancer. [3]

Current guidelines emphasize that the most important thing is not to “find the fat,” but to assess the risk of progression and help the person stop drinking safely and sustainably, because it is continued drinking that determines the prognosis. [4]

Code according to ICD 10 and ICD 11

In the International Classification of Diseases, 10th revision, alcoholic fatty liver disease is classified under category K70 and has the revised code K70.0 "Alcoholic fatty liver." This code is used when fatty liver infiltration is associated specifically with alcohol, rather than metabolic causes. [5]

In the International Classification of Diseases, 11th revision, alcoholic fatty liver disease is included in block DB94 "Alcoholic liver disease" and is coded as DB94.0 "Alcoholic fatty liver." This group also includes alcoholic hepatitis, alcoholic fibrosis, and alcoholic cirrhosis, which helps describe the stage of the process. [6]

Table 1. ICD 10 and ICD 11 codes for alcoholic liver disease

State	ICD 10	ICD 11
Alcoholic fatty liver disease	K70.0	DB94.0
Alcoholic hepatitis	K70.1	DB94.1
Alcoholic liver fibrosis	K70.2	DB94.2
Alcoholic cirrhosis of the liver	K70.3	DB94.3

[7]

Epidemiology

Alcohol-induced fatty liver disease is the most common early manifestation of alcoholic liver disease. According to clinical reviews, fatty infiltration develops in approximately 90% of people who consume large amounts of alcohol over a long period of time, for example, more than 60 grams of pure ethanol per day. [8]

Even with severe fatty infiltration, not everyone progresses, but the risk is not zero. Reviews note that with "pure" alcoholic fatty liver disease, the risk of progression to cirrhosis is approximately 10% over a period of approximately 10 years, and with higher volumes of consumption, the risk increases sharply. [9]

The epidemiological picture is complicated by the fact that early stages are often asymptomatic and underreported. The American Association for the Study of Liver Diseases guidelines emphasize that early stages are difficult to detect without active detection and noninvasive tools for assessing fat and fibrosis. [10]

At the public health level, alcohol-associated liver disease remains a leading cause of severe chronic liver disease and liver transplantation. The 2024 US guidelines describe an increasing disease burden and a significant proportion of mortality associated with harmful alcohol use. [11]

Table 2. Frequency and natural history: guidelines for understanding risk

Indicator	Grade	Comment
The likelihood of fatty infiltration with long-term heavy alcohol consumption	about 90%	The risk increases with dose and duration [12]
Risk of progression of "pure" alcoholic fatty liver disease to cirrhosis	about 10%	Average review scores vary by dose and risk factors [13]
The proportion of people who develop more severe damage with continued use	minority	The transition to inflammation and fibrosis depends on many factors [14]

Reasons

The immediate cause of alcoholic fatty liver disease is the toxic and metabolic effects of ethanol and its breakdown products on liver cells. The liver is forced to process alcohol, energy processes are altered, and fats begin to accumulate faster than they can be utilized. [15]

Acetaldehyde and oxidative stress play a key role: they damage cellular structures, including mitochondria, which disrupts the "burning" of fatty acids. This makes fatty infiltration not just a "deposit" but part of a toxic cascade. [16]

Alcohol also increases the uptake of fatty acids from adipose tissue into the liver and stimulates the formation of triglycerides. With regular consumption, the liver becomes constantly overloaded with fat.

Finally, the contribution of the gut is important: alcohol increases the permeability of the intestinal barrier and increases the entry of bacterial components into the portal vein, which maintains the inflammatory readiness of the liver and increases the risk of the transition from simple fat to inflammation. [17]

Risk factors

The main risk factor is the amount, duration, and pattern of alcohol consumption. Clinical reviews note that regular consumption of 30-50 grams of pure ethanol per day for more than 5 years can lead to alcohol-associated liver disease, with higher doses accelerating the process. [18]

Female gender is associated with greater liver vulnerability to alcohol at comparable doses, as well as a more rapid increase in the burden of alcoholic liver disease in the population. This is attributed to biological differences in alcohol metabolism and hormonal factors. [19]

Obesity and metabolic syndrome increase the toxicity of alcohol. A review of the interaction between obesity and alcohol shows that the combination of these factors significantly increases the risk of fibrosis and cirrhosis compared to each factor alone. [20]

Concomitant liver diseases, such as viral hepatitis, as well as a genetic predisposition, increase the likelihood of progression. The American Association for the Study of Liver Diseases guidelines emphasize the contribution of genetics and comorbid liver diseases to the acceleration of the disease. [21]

Table 3. Risk factors for the progression of alcoholic fatty liver disease

Factor	How does it affect	Practical meaning
High doses and duration of alcohol consumption	increases the risk of fat, inflammation and fibrosis	main controlled factor [22]
Episodes of binge drinking	increases the risk of acute injuries and remission breakdowns	It is important to specify the pattern, not just the “average dose” [23]
Obesity, metabolic syndrome	increases inflammation and fibrosis	parallel correction of weight and metabolism is required [24]
Female gender	increases vulnerability to alcohol toxicity	early detection and prevention are more important [25]
Associated liver diseases and genetics	accelerate progression	screening for other causes of liver disease is needed [26]

Pathogenesis

Alcohol-induced fatty liver disease develops when the balance between fat intake, fat synthesis, and fat utilization shifts toward accumulation. Alcohol simultaneously increases fat production and inhibits its oxidation, causing fat to become trapped in liver cells. [27]

Mitochondrial dysfunction and oxidative stress create the conditions for further damage. In this context, simple fatty infiltration can progress to inflammation and cellular damage, especially with continued use. [28]

The immune component is important even in the early stages. Increased bacterial signaling from the intestine activates Kupffer cells and proinflammatory pathways, increasing the likelihood of progression to alcoholic steatohepatitis. [29]

Clinically important, alcohol withdrawal "breaks" several links in the pathogenesis at once. The American Association for the Study of Liver Diseases guidelines explicitly state that alcohol-associated steatosis is reversible upon cessation of alcohol consumption. [30]

Table 4. The main links of pathogenesis and their clinical consequences

Link	What's happening	What can be changed
A shift in metabolism towards accumulation of triglycerides	fat accumulates in hepatocytes	cessation of alcohol consumption, dietary correction
Oxidative stress	damage to membranes and mitochondria	sobriety, treatment of nutritional deficiencies [31]
Enterohepatic axis	increased inflammatory signals	sobriety, nutritional correction, treatment of concomitant diseases [32]
Inflammatory activation	risk of progression to steatohepatitis	early intervention at the preserved stage [33]

Symptoms

Most people with alcoholic fatty liver disease do not present with any specific complaints. Fatigue, decreased performance, and discomfort in the right upper quadrant are sometimes noted, but these symptoms are nonspecific and may be associated with other causes. [34]

Examination may reveal an enlarged liver without jaundice or signs of severe portal hypertension. This is why the disease is often detected incidentally during an ultrasound examination. [35]

Laboratory abnormalities are usually mild. The American Association for the Study of Liver Diseases guidelines note that among liver enzymes, elevated aspartate aminotransferase and gamma glutamyl transferase more often reflect recent heavy alcohol consumption, but the tests cannot "replace" a conversation about the amount of alcohol consumed. [36]

If jaundice, fever, severe weakness, edema, abdominal distension, or confusion develop, this usually indicates a more severe stage, such as alcoholic hepatitis or decompensated cirrhosis, and requires urgent evaluation.[37]

Classification, forms and stages

Alcohol-associated liver disease is considered a spectrum: alcoholic steatosis, alcoholic steatohepatitis, fibrosis, and cirrhosis. Alcoholic fatty liver disease corresponds to the steatosis stage and is often the first stage to be identified.[38]

From a clinical perspective, it is useful to differentiate the condition into "fatty infiltration without inflammation" and "fatty infiltration with inflammation." The latter carries a higher risk of progression and often requires an in-depth assessment of fibrosis. [39]

The presence and degree of fibrosis are assessed separately, as fibrosis best predicts long-term prognosis. Current guidelines emphasize the importance of noninvasive assessment of fibrosis and broader detection of early stages. [40]

Within the steatosis stage, descriptive formulations are sometimes used based on the extent of fat as determined by imaging or histology, but for practice, it is more important to answer the question: is there fibrosis and are there signs of more severe damage. [41]

Table 5. Stages of alcohol-associated liver disease

Stage	What's happening	Typical signs
Alcoholic steatosis	fat in liver cells	often asymptomatic, moderate changes in tests [42]
Alcoholic steatohepatitis	fat plus inflammation and cell damage	jaundice, increased bilirubin, signs of systemic inflammation [43]
Fibrosis	scarring of liver tissue	may be asymptomatic, assessment of fibrosis is important [44]
Cirrhosis	severe scarring and remodeling of the liver	portal hypertension, complications, risk of liver cancer [45]

Complications and consequences

The main "complication" of alcoholic fatty liver disease is its progression while alcohol consumption continues. Reviews emphasize that almost all heavy drinkers develop steatosis, but a minority progress to cirrhosis, and this minority often has additional risk factors. [46]

Alcoholic hepatitis is the most dangerous intermediate stage: it can develop against the background of existing cirrhosis and dramatically worsen the condition. Current guidelines place great emphasis on early recognition and assessment of the severity of this syndrome. [47]

As cirrhosis develops, complications of portal hypertension arise: ascites, bleeding from esophageal varices, and hepatic encephalopathy. Against this background, even a brief "breakdown" can lead to decompensation. [48]

A separate long-term risk is liver cancer. It increases significantly in cirrhosis, so people with advanced fibrosis and cirrhosis require regular screening programs. [49]

When to see a doctor

A routine consultation is necessary if there is regular alcohol consumption and changes in liver tests or fatty infiltration are detected on ultrasound. Early intervention is most effective because steatosis is reversible. [50]

Urgent medical attention is required if jaundice, fever, severe weakness, dark urine, light-colored stools, or increasing upper abdominal pain occur. This may be consistent with alcoholic hepatitis or other serious conditions. [51]

Immediate assistance is needed if vomiting blood, passing black stools, experiencing a sudden increase in abdominal size, severe swelling, confusion, or drowsiness occurs. These are typical signs of complications of cirrhosis and portal hypertension. [52]

It's also important to consult a doctor if alcohol withdrawal is accompanied by severe tremors, palpitations, sweating, anxiety, insomnia, or seizures. Withdrawal can be dangerous and requires medical attention. [53]

Diagnostics

The first step is an honest assessment of alcohol use: quantity, frequency, binge drinking episodes, attempts to cut back, and consequences. Current guidelines emphasize the need to identify alcohol use disorder, because without treatment, the liver prognosis remains poor. [54]

The second step involves basic blood tests: complete blood count, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, bilirubin, albumin, coagulation parameters, as well as a lipid profile and glucose. These data help assess the extent of the damage and rule out alternative causes. [55]

The third step is instrumental diagnostics. Ultrasound is effective in detecting fatty infiltration, while magnetic resonance imaging (MRI) techniques more accurately quantify fat and help monitor changes. [56]

The fourth step is assessing fibrosis using non-invasive methods, such as elastography, because fibrosis determines the long-term risk of complications. Guidelines emphasize that wider use of non-invasive tools helps identify people at risk of progression earlier. [57]

Liver biopsy is not usually required to confirm alcoholic steatosis if clinical presentation and imaging are typical and other causes have been excluded. It is considered in cases of diagnostic uncertainty, suspected concurrent liver disease, or for accurate staging in controversial cases.[58]

Table 6. Step-by-step diagnosis of alcoholic fatty liver disease

Step	What are they doing?	Why is this necessary?
1	Assessment of alcohol use and signs of withdrawal	confirm causality and risks [59]
2	Blood tests for liver, coagulation, and metabolism	assess the severity and exclude alternatives [60]
3	Ultrasound examination of the liver	confirm steatosis and associated changes [61]
4	Elastography or other non-invasive methods	assess fibrosis and prognosis [62]
5	Liver biopsy in controversial cases	clarify the diagnosis and stage if there is insufficient data [63]

Differential diagnosis

Fatty liver disease is not always associated with alcohol. A common alternative is metabolically induced fatty liver disease associated with obesity, diabetes, and dyslipidemia. When factors combine, alcohol and metabolic disorders can exacerbate each other. [64]

It is important to exclude viral hepatitis, drug-induced liver injury, and autoimmune liver diseases, as their treatment strategies and prognosis differ. Current guidelines recommend also assessing concomitant liver diseases, as they accelerate progression with alcohol consumption. [65]

A separate challenge is distinguishing simple steatosis from alcoholic steatohepatitis and from severe fibrosis or cirrhosis. If inflammation and severe stages are suspected, clinical features, bilirubin, coagulation parameters, albumin, signs of portal hypertension, and fibrosis assessment methods are used. [66]

If a person denies alcohol use or the data are inconsistent, alcohol biomarkers may be used, but they do not replace clinical assessment. The 2024 US guidelines emphasize the role of biomarkers in diagnosis and monitoring, particularly in controversial situations. [67]

Table 7. Common causes of fatty liver infiltration and distinctive features

Cause	Typical tips	What helps to clarify
Alcoholic fatty liver disease	regular or occasional excessive use, increased gamma glutamyl transferase	careful anamnesis, dynamics during sobriety [68]
Metabolic fatty liver disease	obesity, diabetes mellitus, dyslipidemia	Metabolic assessment, weight loss [69]
Drug-induced liver injury	connection with the start of taking the drug	drug history, withdrawal of suspected drug [70]
Viral hepatitis	risk factors, characteristic markers	serological tests [71]
Autoimmune liver diseases	autoantibodies, other autoimmune diseases	immunological tests, sometimes biopsy [72]

Treatment

The mainstay of treatment for alcoholic fatty liver disease is complete abstinence from alcohol, as this intervention simultaneously addresses the underlying cause and initiates liver recovery. The American Association for the Study of Liver Diseases guidelines explicitly state that treatment for alcohol-associated steatosis consists of alcohol abstinence and that steatosis is reversible upon cessation of consumption. [73]

Safe alcohol withdrawal is important. Long-term use can lead to dangerous withdrawal symptoms, so if withdrawal symptoms are severe, medical support is recommended, sometimes with inpatient or day hospital detoxification. [74]

Treatment for alcohol use disorder is required in parallel, otherwise the risk of relapse remains high. Guidelines emphasize that without sustained sobriety, any "liver" measures have limited effectiveness. [75]

Psychosocial methods include motivational counseling, cognitive behavioral approaches, family support, and peer support programs. The choice of format depends on the severity of the addiction, living conditions, and the presence of co-occurring mental disorders. [76]

Medication for sobriety support is selected taking into account liver function. Naltrexone is contraindicated in acute hepatitis and liver failure, so the decision should be especially cautious in cases of active liver damage. [77]

Acamprosate is not metabolized by the liver and is described in clinical reports as an option that can be used even in severe liver disease, but it requires monitoring of renal function. This often makes it preferred in people with severe liver disease, unless there are renal contraindications. [78]

Baclofen is one of the most studied options for people with chronic liver disease, including cirrhosis, although study results are mixed and careful monitoring of side effects is required. American Clinical Practice Guidelines for Patient Management in Hepatology list it as the most studied drug for these situations. [79]

Gabapentin and topiramate are considered additional options for reducing cravings and the risk of relapse, particularly in cases of severe withdrawal symptoms and sleep disturbances, but these are typically "off-label" and require individualized treatment. Gabapentin and topiramate have clinical trial and meta-analysis data demonstrating their effectiveness in reducing use and maintaining abstinence. [80]

Nutrition and deficiencies are critically important because people with harmful alcohol consumption often have protein-energy malnutrition and vitamin deficiencies, which impair liver recovery. Practical recommendations typically emphasize adequate protein and calorie intake, as well as the prevention of thiamine deficiency, especially in those at risk for neurological complications. [81]

If obesity, diabetes, and dyslipidemia are present, their correction becomes part of the treatment of alcoholic fatty liver disease, because the combination of metabolic factors and alcohol accelerates fibrosis. A realistic goal is gradual weight loss, regular physical activity, and glycemic control, while maintaining complete abstinence from alcohol. [82]

Table 8. Maintaining sobriety in liver disease: practical guidelines

Approach	What does it give?	Important limitations
Acamprosate	support of abstinence, minimal load on the liver	monitoring of renal function is required [83]
Naltrexone	reducing cravings and the likelihood of heavy episodes of use	contraindicated in acute hepatitis and liver failure [84]
Baclofen	variant in chronic liver disease, studied in some patients	the effect is heterogeneous, monitoring of side effects is necessary [85]
Gabapentin	may reduce consumption and improve sleep, especially during withdrawal symptoms	individual selection, monitoring of sedative effect [86]
Topiramate	According to a meta-analysis, it improves consumption rates	side effects from the nervous system, dose selection [87]
Disulfiram	"barrier" method for motivated patients	the risk of drug-induced liver injury is known [88]

Prevention

The most effective prevention of alcoholic fatty liver disease is abstinence from harmful alcohol consumption. Once fatty liver disease has been diagnosed, prevention of progression is limited to sustained abstinence and treatment of alcohol use disorder. [89]

The second line of prevention is control of metabolic factors: weight loss, treatment of diabetes mellitus, and dyslipidemia. This is especially important because metabolic disturbances exacerbate alcohol-induced liver damage. [90]

Vaccination and prophylaxis against viral hepatitis are important if there is a risk, as the combination of alcohol and other liver diseases accelerates fibrosis. At the same time, medications should be reviewed and potentially hepatotoxic substances should be avoided unless necessary. [91]

Relapse prevention includes a relapse plan, medical supervision, psychotherapeutic support, and, if necessary, drug therapy for cravings. Current guidelines emphasize that long-term sobriety is what determines outcome. [92]

Forecast

In alcoholic fatty liver disease, the prognosis is usually good if alcohol consumption is stopped. Official clinical guidelines from the UK National Health Service emphasize the reversibility of fatty liver disease with alcohol cessation. [93]

With continued use, the prognosis becomes variable: some people remain in the steatosis stage, while others develop inflammation and fibrosis. Reviews show that the risk of progression increases sharply with high consumption volumes and in the presence of obesity and metabolic syndrome. [94]

At the stage of advanced fibrosis and cirrhosis, the prognosis is determined by complications of portal hypertension and the risk of liver cancer, as well as the ability to maintain abstinence. The American Association for the Study of Liver Diseases guidelines emphasize that the outcome of cirrhosis is critically dependent on a person's ability to abstain from alcohol. [95]

Even in established cirrhosis, alcohol abstinence can improve survival and reduce the risk of decompensation, although a complete "return to normal" is usually unattainable at this stage. Therefore, early detection and early abstinence are of the utmost value. [96]

FAQ

Can alcoholic fatty liver disease be "cured" with pills if you continue drinking? No, because the underlying cause remains. Current guidelines recommend that the treatment for alcoholic fatty liver disease is to stop drinking alcohol, and this is what makes the condition reversible. [97]

How long after abstaining from alcohol can the liver improve? In some people, signs of steatosis improve within a few weeks, but it's safer to rely on individual test results and imaging. National Health Service clinical guidelines indicate that fatty liver disease is reversible with sufficient abstinence. [98]

Does everyone need a liver biopsy? Usually not. The American Association for the Study of Liver Diseases guidelines note that a biopsy is rarely needed to diagnose alcoholic steatosis if the clinical presentation and imaging are typical. [99]

Is it okay to drink "a little" occasionally if things are improving? For people with confirmed alcoholic liver disease, it's safer to consider the goal as sustained sobriety, as even "moderate" drinking often leads to a return to harmful patterns. Guidelines emphasize supporting abstinence as a key prognostic factor. [100]

What tests are most important for monitoring? Typically, liver enzymes, bilirubin, albumin, and coagulation parameters are monitored, and steatosis and fibrosis are periodically assessed instrumentally. Guidelines emphasize the role of noninvasive fibrosis assessment for prognosis. [101]

Key points from guidelines and expert opinions

David W. Crabb, MD, professor, Indiana University School of Medicine, co-author of the American Association for the Study of Liver Diseases guidelines, formulates the key principle this way: “Alcohol-associated steatosis is reversible with cessation of alcohol consumption.” Translation from English. [102]

Gene Im, MD, Icahn School of Medicine at Mount Sinai, and co-authors in the same paper emphasize practical tactics: “Treatment of alcohol-associated steatosis consists of alcohol avoidance.” Translation from English. [103]

Jessica L. Mellinger, MD, University of Michigan Hospitals and Health Centers, on the expert panel, highlights the clinical challenge: early stages are often missed, making noninvasive tools for assessing steatosis and fibrosis important for early detection of risk for progression. Translation and summary of the guideline position. [104]

The 2024 American Clinical Practice Guideline for Alcohol-Associated Liver Disease emphasizes that harmful alcohol use is a major risk factor for liver disease and that the disease burden is increasing, particularly in young adults and women. This is important for both prevention and early referral. [105]

A separate clinical point of importance for practice: naltrexone has limitations in active liver disease. Clinical data indicate that it is contraindicated in acute hepatitis and liver failure, so the choice of a medication for maintaining sobriety should take into account the stage of liver disease and alternatives. [106]